Evidence map›Paper›PMID 29422766›Full record

ArticleMolecular vision2018

Inhibition of YAP ameliorates choroidal neovascularization via inhibiting endothelial cell proliferation.

Zhenzhen Yan, Haihong Shi, Rongrong Zhu, Lele Li, Bai Qin, Lihua Kang, Hui Chen, Huaijin Guan

Open access · greenAbstract read
In one paragraph

Article in Molecular vision, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

  1. The Hippo signalling pathway and its impact on eye diseases.Journal of cellular and molecular medicine · 2024
    Pooled it
  2. Article
  3. Article
  4. Review
  5. Beyond VEGF: Targeting Inflammation and Other Pathways for Treatment of Retinal Disease.The Journal of pharmacology and experimental therapeutics · 2023
    Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Zhenzhen YanDepartment of Ophthalmology, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, China.
Haihong ShiDepartment of Ophthalmology, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, China.
Rongrong ZhuDepartment of Ophthalmology, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, China.
Lele LiDepartment of Ophthalmology, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, China.
Bai QinDepartment of Ophthalmology, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, China.
Lihua KangDepartment of Ophthalmology, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, China.
Hui ChenDepartment of Ophthalmology, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, China.
Huaijin GuanDepartment of Ophthalmology, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, China.
Affiliated Hospital of Nantong University · CNNantong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Age-related macular degeneration (AMD) is the leading cause of central visual loss among patients over the age of 55 years worldwide. Neovascular-type AMD (nAMD) accounts for approximately 10% of patients with AMD and is characterized by choroidal neovascularization (CNV). The proliferation of choroidal endothelial cells (CECs) is one important step in the formation of new vessels. Transcriptional coactivator Yes-associated protein (YAP) can promote the proliferation of multiple cancer cells, corneal endothelial cells, and vascular smooth muscle cells, which participate in angiogenesis. This study intends to reveal the expression and functions of YAP during the CNV process. Methods: In the study, a mouse CNV model was generated by laser photocoagulation. YAP expression was detected with western blotting and immunohistochemistry. YAP siRNA and ranibizumab, a VEGF monoclonal antibody, were injected intravitreally in CNV mice. The YAP and VEGF expression levels after injection were detected with western blotting. The incidence and leakage area of CNV were measured with fundus fluorescein angiography, choroidal flat mounting, and hematoxylin and eosin (HE) staining. Immunofluorescent double staining was used to detect YAP cellular localization with CD31 (an endothelial cell marker) antibody. Proliferating cell nuclear antigen (PCNA) expression in CNV mice without or with YAP siRNA intravitreal injection and the colocalization of PCNA and CD31 were measured with western blotting and immunofluorescent double staining, respectively. Results: YAP expression increased following laser exposure, in accordance with vascular endothelial growth factor (VEGF) expression. YAP siRNA and ranibizumab decreased VEGF expression and the incidence and leakage area of CNV. YAP was localized in the vascular endothelium within the CNV site. Additionally, after laser exposure, YAP siRNA inhibited the increased expression of PCNA, which was colocalized with endothelial cells. Conclusions: This study showed that YAP upregulation promoted CNV formation by upregulating the proliferation of endothelial cells, providing evidence for the molecular mechanisms of CNV and suggesting a novel molecular target for nAMD treatment.

Indexed as

Adaptor Proteins, Signal TransducingAnimalsCell Cycle ProteinsCell ProliferationChoroidChoroidal NeovascularizationDisease Models, AnimalEndothelial CellsGene Expression RegulationHumansIntravitreal InjectionsLight CoagulationMacular DegenerationMiceMice, Inbred C57BLPhosphoproteinsAdaptor Proteins, Signal TransducingCell Cycle ProteinsPhosphoproteinsPlatelet Endothelial Cell Adhesion Molecule-1Proliferating Cell Nuclear AntigenRanibizumabRNA, Small InterferingVascular Endothelial Growth Factor Avascular endothelial growth factor A, mouseYap1 protein, mouseYAP-Signaling Proteins

Identifiers

PMID29422766
PMCPMC5800432
OpenAlexW2892741971

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.